Last reviewed · How we verify
Lipo-PGE1
Lipo-PGE1 is a Prostaglandin E1 analog Small molecule drug developed by West China Hospital. It is currently FDA-approved for Peripheral arterial occlusive disease, Diabetic angiopathy, Ischemic ulcers. Also known as: alprostadil, aspirin, clopidogrel, antidiabetic drugs.
Lipo-PGE1 is a lipid-formulated prostaglandin E1 that promotes vasodilation and improves blood flow by activating prostanoid receptors on vascular smooth muscle and endothelial cells.
Lipo-PGE1 is a small molecule intervention used in clinical trials for conditions such as veno-occlusive disease, retained placenta, and respiratory insufficiency in infants and newborns. It is being studied as a potential treatment in a pharmacokinetic study for preventing veno-occlusive disease after hematopoietic stem cell transplantation.
At a glance
| Generic name | Lipo-PGE1 |
|---|---|
| Also known as | alprostadil, aspirin, clopidogrel, antidiabetic drugs, Prostaglandin E1 incorporated in lipid microspheres |
| Sponsor | West China Hospital |
| Drug class | Prostaglandin E1 analog |
| Target | Prostaglandin E receptor (EP receptors) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
PGE1 is a naturally occurring prostaglandin that binds to EP receptors on vascular tissue, triggering relaxation of smooth muscle and increasing cAMP levels, which leads to vasodilation and improved microcirculation. The lipid formulation enhances stability and bioavailability. This mechanism helps restore blood flow to ischemic tissues and reduce platelet aggregation.
Approved indications
- Peripheral arterial occlusive disease
- Diabetic angiopathy
- Ischemic ulcers
Common side effects
- Flushing
- Headache
- Dizziness
- Gastrointestinal discomfort
- Hypotension
Key clinical trials
- Cervical Ripening With Misoprostol vs Isosorbide Mononitrate ; A Parallel -Arm Randomized Controlled Trial (NA)
- LOng COvid COmorbidities: Andrological, Reproductive, Sexual Dysfunctions in Patients Recovered From COVID-19
- Radiological Evaluation of the Penis Before and After a Botox Injection (PHASE1, PHASE2)
- Cri Analog PG1 Effectiveness and Safety in Covid-19 (PHASE2)
- Efficacy and Safety of Oral Misoprostol 25 μg vs. Vaginal Dinoprostone in Induction of Labor at Term
- PGE1 as Additive Anticoagulant in ECMO-Therapy (PHASE2)
- Comparison of the VerifyNow® Aspirin Test and PRUTest® Platelet Reactivity Tests With Investigational Reagent to Reagents Registered in Japan
- Cervical Ripening in Premature Rupture of Membranes (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lipo-PGE1 CI brief — competitive landscape report
- Lipo-PGE1 updates RSS · CI watch RSS
- West China Hospital portfolio CI
Frequently asked questions about Lipo-PGE1
What is Lipo-PGE1?
How does Lipo-PGE1 work?
What is Lipo-PGE1 used for?
Who makes Lipo-PGE1?
Is Lipo-PGE1 also known as anything else?
What drug class is Lipo-PGE1 in?
What development phase is Lipo-PGE1 in?
What are the side effects of Lipo-PGE1?
What does Lipo-PGE1 target?
Related
- Drug class: All Prostaglandin E1 analog drugs
- Target: All drugs targeting Prostaglandin E receptor (EP receptors)
- Manufacturer: West China Hospital — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Peripheral arterial occlusive disease
- Indication: Drugs for Diabetic angiopathy
- Indication: Drugs for Ischemic ulcers
- Also known as: alprostadil, aspirin, clopidogrel, antidiabetic drugs, Prostaglandin E1 incorporated in lipid microspheres
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing